TABLE 17.
Comparison of the in vitro susceptibilities of Candida isolates collected before (1992 to 2000) and after (2001 to 2004) the clinical introduction of caspofungina
| Yr | No. of isolates tested | Cumulative % susceptible at indicated MIC (μg/ml)
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.007 | 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | >8 | ||
| 1992-2000 | 3,322b | 23 | 38 | 68 | 84 | 88 | 93 | 98 | 99 | 99 | 99 | 99 | 100 |
| 2001 | 1,783 | 16 | 35 | 68 | 83 | 88 | 95 | 99 | 99 | 99 | 100 | ||
| 2002 | 2,239 | 28 | 42 | 68 | 81 | 85 | 91 | 98 | 99 | 99 | 99 | 99 | 100 |
| 2003 | 2,287 | 7 | 28 | 60 | 78 | 81 | 89 | 98 | 99 | 99 | 99 | 99 | 100 |
| 2004 | 1,888 | 1 | 14 | 54 | 78 | 82 | 89 | 98 | 99 | 99 | 99 | 99 | 100 |
| 2001-2004 | 8,197 | 13 | 30 | 62 | 80 | 84 | 91 | 98 | 99 | 99 | 99 | 99 | 100 |
a
All isolates were from blood or normally sterile-site infections. All isolates were tested in RPMI 1640 broth with a 24-h incubation period and a prominent reduction endpoint criterion (MIC-2). Data are compiled from reference 224.
b
Eight of the 11 isolates for which the MICs were ≥2 μg/ml are glucan synthesis mutants.